Intrommune - About the company
Intrommune is a series A company based in New York City (United States), founded in 2015 by Michael Nelson and Michael Nelson. It operates as a Developing oral mucosal immunotherapy toothpaste for food allergy management. Intrommune has raised $3.28M in funding from Red Bear Angels. The company has 194 active competitors, including 60 funded and 46 that have exited. Its top competitors include companies like BeiGene, BioNTech and DBV Technologies.
Company Details
Developing oral mucosal immunotherapy toothpaste for food allergy management. The company is a biotechnology firm focused on simplifying allergy immunotherapy through its novel drug delivery platform. This platform embeds therapeutic agents in a toothpaste, offering a convenient daily treatment for food allergies. Their oral mucosal immunotherapy (OMIT) approach delivers allergenic proteins to the oral cavity, potentially driving immune tolerance without ingestion. The mission is to develop safe, effective, and easy-to-use solutions for food allergy management, supporting early allergen introduction, advancing OMIT treatment options, and empowering physicians with versatile patient care solutions. They are committed to the wellbeing of those with food allergies.
- Website
- intrommune.com
- Social
- Registered Address
- 20 West 125th Street, Suite#1, New York, NY
Key Metrics
Founded Year
2015
Location
New York City, United States
Stage
Series A
Total Funding
$3.28M in 2 rounds
Latest Funding Round
Investors
Ranked
102nd among 194 active competitors
Employee Count
14 as on Aug 31, 2026
Legal entities associated with Intrommune
Intrommune is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ZENII, LLC CIN: 0001736977 , United States, Active | - | 2 (As on Dec 31, 2018) | - |
Sign up to download Intrommune's company profile
Intrommune's funding and investors
Intrommune has raised a total funding of $3.28M over 2 rounds. Its first funding round was on Nov 08, 2018. Intrommune has 1 institutional investor.
Here is the list of recent funding rounds of Intrommune:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 06, 2023 | 1839383 | Series A | 6943405 | 1477362 | 8207394 | 4701081 |
Nov 08, 2018 | 1591223 | Series A | 1692709 | 6195626 | 4837965 |
Access funding benchmarks and valuations. Sign up today!View details of Intrommune's funding rounds and investors
Intrommune's founders and board of directors
Founder? Claim ProfileThe founders of Intrommune are Michael Nelson and Michael Nelson. Michael Nelson is the CEO of Intrommune.
Here are the details of Intrommune's key team members:
- Michael Nelson: Founder & CEO of Intrommune and founder of 2 other companies, Allovate and Immunovent. Contact Info: 3 email addresses
- Michael Nelson: Founder & CEO of Intrommune.
View details of Intrommune's Founder profiles and Board Members
Intrommune's employee count trend
Intrommune has 14 employees as of Aug 26. Here is Intrommune's employee count trend over the years:
Uncover Intrommune's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Intrommune's Competitors and alternates
Top competitors of Intrommune include BeiGene, BioNTech and DBV Technologies. Here is the list of Top 10 competitors of Intrommune, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 69/100 | ||
3rd | DBV Technologies 2002, Bagneux (France), Public | Developer of products for the treatment of various kinds of food allergies | $68.9M | 68/100 | |
4th | Serum Institute of India 1966, Pune (India), Funding Raised | Manufacturer of vaccines and immuno-biological drugs for infectious diseases | - | 62/100 | |
5th | Stallergenes Greer 2013, London (United Kingdom), Acquired | Developing allergen immunotherapy (vaccine) for respiratory allergies | - | 62/100 | |
6th | AC Immune 2003, Lausanne (Switzerland), Public | Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative diseases | $120M | 61/100 | |
7th |  Mabylon 2015, Schlieren (Switzerland), Series B | Developer of therapeutics for allergies and neurodegenerative diseases | $37M | 60/100 | |
8th |  RAPT 2015, San Francisco (United States), Acquired | Provider of immunology-based drug for oncology and inflammatory diseases | $199M | 59/100 | |
9th | Vir Biotechnology 2017, San Francisco (United States), Public | Developer of therapeutics for the treatment of infectious diseases | $216M | 59/100 | |
10th | Cidara Therapeutics 2013, San Diego (United States), Acquired | Developer of novel anti-infectives for infectious diseases (bacterial and fungal) | $78.4M | 58/100 | |
102nd | Intrommune 2015, New York City (United States), Series A | Developing oral mucosal immunotherapy toothpaste for food allergy management | $3.28M | 31/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Intrommune's competitors? Click here to see the top ones
Intrommune's Investments and acquisitions
Intrommune has made no investments or acquisitions yet.
Reports related to Intrommune
Here is the latest report on Intrommune's sector:
News related to Intrommune
Filter this list•
Intrommune Therapeutics has filed a notice of an exempt offering of securities to raise $10,000,000.00 in New Debt Financing.intelligence360•Jan 31, 2024•Intrommune
•
•
Trial investigating peanut allergy immunotherapy hits final milestonePharmaceutical Technology•Jul 26, 2023•Intrommune
•
Intrommune Therapeutics Names Nandini Murthy as Head of RegulatoryGlobeNewswire•Jun 01, 2022•Intrommune, Enemconsulting
•
Intrommune Therapeutics Appoints Moises V. “Moe” Vela, Jr. to its Business Advisory BoardGlobeNewswire•Aug 11, 2021•Intrommune, The Vela Group
•
Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301Pipelinereview•Feb 04, 2021•Intrommune
•
Intrommune Therapeutics moving its peanut allergy treatment through the FDA approval processProactive Investors•Jan 13, 2020•Intrommune
•
Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee VoteGlobeNewswire•Sep 16, 2019•Intrommune
•
Intrommune Therapeutics Receives Support from Allergy & Asthma NetworkGlobeNewswire•Sep 13, 2019•Intrommune
•
Newly Published Findings Validate Intrommune’s Approach to Treating Peanut and Other Food AllergiesGlobeNewswire•Sep 05, 2019•Intrommune
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Intrommune
Explore our recently published companies
- Am Jain College - Chennai based, Unfunded company
- CommerceShop - Atlanta based, 2009 founded, Unfunded company
- Ukrainian State University of Railway - Ukraine based, Unfunded company
- Limitless Business - 1999 founded, Unfunded company
- Carrelle - Los Angeles based, 2018 founded, Unfunded company
- TIPSY FASHIONS - India based, 2011 founded, Unfunded company
